

MAP Clinician Workgroup Input on Finalized PQRS Measures

MAP reviews measures under consideration in the context of their contributions to finalized program measure sets. Prior MAP experience has demonstrated that the winter pre-rulemaking in-person meeting timing does not allow sufficient time to review finalized measure sets before reviewing measures under consideration. Additionally, HHS has asked MAP to review a large number of measures under consideration under challenging time constraints during the past two pre-rulemaking cycles. To address these concerns, MAP is reviewing finalized measure sets in advance of the December pre-rulemaking meetings. Specifically, the MAP Clinician Workgroup will:

- Provide input on measures for the Physician Quality Reporting System (PQRS); and
- Consider whether PQRS measures should also be used in Physician Compare and the Value-Based Payment Modifier (VBPM).

The MAP Clinician Workgroup began this effort during the August 29 web meeting (meeting summary and table of measure input can be found <u>here</u>), reviewing finalized PQRS measures in the areas of cardiovascular, endocrine, renal, neurology, and behavioral health conditions. During our December 2 web meeting, the workgroup will review the remaining PQRS measures in the following areas: CAHPS, cancer, care coordination, head eyes ears nose throat (HEENT), inflammatory bowel disease, imaging, infectious disease, musculoskeletal, neurological, obesity, perinatal and reproductive health, respiratory, safety, and surgery. This document provides the results of the pre-meeting exercise where workgroup members were asked the following about each measure:

- Should the measure remain in PQRS?
- Briefly describe your rationale for removing measures from PQRS and any additional insights regarding the measure.
- For measures that should remain in PQRS, should the measure also be included in Physician Compare and/or VBPM?
- Briefly describe your rationale for inclusion/exclusion in Physician Compare and/or VBPM and any additional insights regarding the measure.

During our web meeting, we will provide an overview of the workgroup exercise results, workgroup members will discuss the results, and then make final determinations. The discussion items highlight areas where there was a lack of agreement among workgroup members.

CAHPS

Table Row #	Measure # and NQF Endorsement Status	Measure Title (Abbreviated)
1	0005 Endorsed	CAHPS Clinician/Group Surveys - (Adult Primary Care, Pediatric Care, and Specialist Care Surveys)
3	0166 Endorsed	HCAHPS

PQRS Measures to Include in Physician Compare and Value-Based Payment Modifier

Measures to Retain or Include in Physician Quality Reporting System

Table Row #	Measure # and NQF Endorsement Status	Measure Title (Abbreviated)
4	M3007 Not Endorsed	CG CAHPS for ACOs

Table	Measure # and NQF	Measure Title (Abbreviated)
Row #	Endorsement Status	
2	0006 Endorsed	CAHPS Health Plan Survey v 4.0 - Adult questionnaire

Cancer

PQRS Measures to Include in Physician Compare and Value-Based Payment Modifier

Table Row #	Measure # and NQF Endorsement Status	Measure Title (Abbreviated)
7	N0031 Not Endorsed - Endorsement Removed	Breast Cancer Screening
12	0032 Endorsed	Cervical Cancer Screening
13	0034 Endorsed	Colorectal Cancer Screening
26	0658 Endorsed	Endoscopy/Poly Surveillance: Appropriate follow-up interval for normal colonoscopy in average risk patients
27	0659 Endorsed	Endoscopy/Poly Surveillance: Colonoscopy Interval for Patients with a History of Adenomatous Polyps- Avoidance of Inappropriate Use
28	0383 Endorsed	Oncology: Plan of Care for Pain – Medical Oncology and Radiation Oncology (paired with 0384)
29	0384 Endorsed	Oncology: Pain Intensity Quantified – Medical Oncology and Radiation Oncology (paired with 0383)
30	0389 Endorsed	Prostate Cancer: Avoidance of Overuse Measure – Bone Scan for Staging Low-Risk Patients

Table Row #	Measure # and NQF Endorsement Status	Measure Title (Abbreviated)
1	0387 Endorsed	Oncology: Hormonal therapy for stage IC through IIIC, ER/PR positive breast cancer
2	0391 Endorsed	Breast Cancer Resection Pathology Reporting- pT category (primary tumor) and pN category (regional lymph nodes) with histologic grade
4	M1057 Not Endorsed	251 Immunohistochemical (IHC) Evaluation of Human Epidermal Growth Factor Receptor 2 Testing (HER2) for Breast Cancer Patients
5	M1100 Not Endorsed	263 Preoperative Diagnosis of Breast Cancer
6	M1101 Not Endorsed	264 Sentinel Lymph Node Biopsy for Invasive Breast Cancer
8	0386 Endorsed	Oncology: Cancer Stage Documented
9	0455 Endorsed	Recording of Clinical Stage for Lung Cancer and Esophageal Cancer Resection
10	0457 Endorsed	Recording of Performance Status (Zubrod, Karnofsky, WHO or ECOG Performance Status) Prior to Lung or Esophageal Cancer Resection
11	M2442 Not Endorsed	Radiation Dose Optimization: Images Available for Patient Follow-up and Comparison Purposes
14	0385 Endorsed	Oncology: Chemotherapy for Stage IIIA through IIIC Colon Cancer Patients
15	0392 Endorsed	Colorectal Cancer Resection Pathology Reporting- pT category (primary tumor) and pN category (regional lymph nodes) with histologic grade
16	M2938 Not Endorsed	Screening Colonoscopy Adenoma Detection Rate Measure
17	1854 Endorsed	Barrett's Esophagus

18	0377 Endorsed	Myelodysplastic Syndrome (MDS) and Acute Leukemias – Baseline Cytogenetic Testing Performed on Bone Marrow
19	0378 Endorsed	MDS: Documentation of Iron Stores in Patients Receiving Erythropoietin Therapy
20	0379 Endorsed	Chronic Lymphocytic Leukemia (CLL) – Baseline Flow Cytometry
21	0380 Endorsed	Multiple Myeloma – Treatment with Bisphosphonates
22	M1882 Not Endorsed	Radiation Dose Optimization: Cumulative Count of Potential High Dose Radiation Imaging Studies: CT Scans and Cardiac Nuclear Medicine Scans
23	M1883 Not Endorsed	Radiation Dose Optimization: Utilization of a Standardized Nomenclature for CT Imaging Description
24	M1888 Not Endorsed	Radiation Dose Optimization: Search for Prior Imaging Studies through a Secure, Authorized, Media-free, Shared Archive
25	M2443 Not Endorsed	Radiation Dose Optimization: Reporting to a Radiation Dose Index Registry
32	1853 Endorsed	Radical Prostatectomy Pathology Reporting
33	0650 Endorsed	Melanoma Continuity of Care – Recall System

Measures to Remove or Exclude from Physician Quality Reporting System

Table Row #	Measure # and NQF Endorsement Status	Measure Title (Abbreviated)
34	N0561 Not Endorsed - Endorsement Removed	Melanoma Coordination of Care

Status to Be Determined for inclusion in Physician Compare and Value-Based Payment Modifier

Table Row #	Measure # and NQF Endorsement Status	Measure Title (Abbreviated)
3	0508 Endorsed	Inappropriate use of "probably benign" assessment category in mammography screening
31	0390 Endorsed	Prostate Cancer: Adjuvant Hormonal Therapy for High-Risk Patients

Discussion/Notes

- Workgroup members were split on recommending NQF #508 (Row #3) for inclusion in Physician Compare and Value-Based Payment Modifier. Some commenters raised concerns about whether the measure is topped out.
- Workgroup members were also split on recommending NQF #0390 (Row# 31) in Physician Compare and Value-Based Payment Modifier program. Comments for inclusion noted that it is a disparities sensitive measure. Comments not recommending the measure for inclusion cited its high performance rate.

Care Coordination

Measures to Retain or Include in Physician Quality Reporting System

Table Row #	Measure # and NQF Endorsement Status	Measure Title (Abbreviated)
1	0495 Endorsed	Median Time from ED Arrival to ED Departure for Admitted ED Patients
2	0643 Endorsed	Cardiac Rehabilitation Patient Referral From an Outpatient Setting
3	M2277 Not Endorsed	Closing the referral loop: receipt of specialist report

Table Row #	Measure # and NQF Endorsement Status	Measure Title (Abbreviated)
4	N0645 Not Endorsed - Endorsement Removed	Biopsy Follow-up

Head Eyes Ears Nose Throat (HEENT)

Table Row #	Measure # and NQF Endorsement Status	Measure Title (Abbreviated)
1	0564 Endorsed	Complications within 30 Days Following Cataract Surgery Requiring Additional Surgical Procedures
2	0565 Endorsed	Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery
3	1536 Endorsed	Cataracts: Improvement in Patient's Visual Function within 90 Days Following Cataract Surgery
6	0654 Endorsed	Acute Otitis Externa: Systemic antimicrobial therapy – Avoidance of inappropriate use
11	1335 Endorsed	Children Who Have Dental Decay or Cavities
13	0002 Endorsed	Appropriate testing for children with pharyngitis

PQRS Measures to Include in Physician Compare and Value-Based Payment Modifier

Measures to Retain or Include in Physician Quality Reporting System

Table Row #	Measure # and NQF Endorsement Status	Measure Title (Abbreviated)
4	M1006 Not Endorsed	304 Cataracts: Patient Satisfaction within 90 Days Following Cataract Surgery
5	0653 Endorsed	Acute Otitis Externa: Topical therapy
7	0086 Endorsed	Primary Open Angle Glaucoma: Optic Nerve Evaluation
8	0563 Endorsed	Primary Open-Angle Glaucoma: Reduction of Intraocular Pressure by 15% or Documentation of a Plan of Care
12	1419 Endorsed	Primary Caries Prevention Intervention as Part of Well/III Child Care as Offered by Primary Care Medical Providers
14	0087 Endorsed	Age-Related Macular Degeneration: Dilated Macular Examination
15	0566 Endorsed	Age-Related Macular Degeneration (AMD): Counseling on Antioxidant Supplement

Table Row #	Measure # and NQF Endorsement Status	Measure Title (Abbreviated)
9	M1080 Not Endorsed	261 Referral for Otologic Evaluation for Patients with Acute or Chronic Dizziness
10	M287 Not Endorsed	188 Referral for Otologic Evaluation for Patients with Congenital or Traumatic Deformity of the Ear

Inflammatory Bowel Disease

Table Row #	Measure # and NQF Endorsement Status	Measure Title (Abbreviated)
1	M1084 Not Endorsed	269 Inflammatory Bowel Disease (IBD): Type, Anatomic Location and Activity All Documented
2	M1085 Not Endorsed	270 Inflammatory Bowel Disease (IBD): Preventive Care: Corticosteroid Sparing Therapy
3	M1086 Not Endorsed	271 Inflammatory Bowel Disease (IBD): Preventive Care: Corticosteroid Related latrogenic Injury – Bone Loss Assessment
4	M1087 Not Endorsed	272 Inflammatory Bowel Disease (IBD): Preventive Care: Influenza Immunization
5	M1088 Not Endorsed	273 Inflammatory Bowel Disease (IBD): Preventive Care: Pneumococcal Immunization
6	M1089 Not Endorsed	274 Inflammatory Bowel Disease (IBD): Screening for Latent TB Before Initiating Anti-TNF Therapy
7	M1090 Not Endorsed	275 Inflammatory Bowel Disease (IBD): Hepatitis B Assessment Before Initiating Anti-TNF Therapy

Infectious Disease

PQRS Measures to Include in Physician Compare and Value-Based Payment Modifier

Table Row #	Measure # and NQF Endorsement Status	Measure Title (Abbreviated)
21	0038 Endorsed	Childhood Immunization Status
22	0041 Endorsed	Influenza Immunization
23	0043 Endorsed	Pneumonia vaccination status for older adults
25	0033 Endorsed	Chlamydia screening in women

Measures to Retain or Include in Physician Quality Reporting System

Table Row #	Measure # and NQF Endorsement Status	Measure Title (Abbreviated)
1	0393 Endorsed	Hepatitis C: Testing for Chronic Hepatitis C – Confirmation of Hepatitis C Viremia
2	0395 Endorsed	Paired Measure: Hepatitis C RNA Testing Before Initiating Treatment (paired with 0396)
3	0396 Endorsed	Paired Measure: HCV Genotype Testing Prior to Treatment (paired with 0395)
4	0398 Endorsed	Hepatitis C: HCV RNA Testing at Week 12 of Treatment
5	0399 Endorsed	Paired Measure: Hepatitis C: Hepatitis A Vaccination (paired with 0400)
10	0404 Endorsed	HIV/AIDS: CD4+ Cell Count or CD4+ Percentage
11	0405 Endorsed	HIV/AIDS: Pneumocystis jiroveci pneumonia (PCP) prophylaxis
12	0409 Endorsed	HIV/AIDS: Sexually Transmitted Diseases - Chlamydia and Gonorrhea Screenings
13	2079 Endorsed	HIV medical visit frequency
14	2080 Endorsed	Gap in HIV medical visits
15	2082 Endorsed	HIV viral load suppression
16	2083 Endorsed	Prescription of HIV Antiretroviral Therapy
24	1653 Endorsed	Pneumococcal Immunization (PPV 23)

Table Row #	Measure # and NQF Endorsement Status	Measure Title (Abbreviated)
6	N0394 Not Endorsed - Endorsement Removed	Hepatitis C: Counseling Regarding Use of Contraception Prior to Antiviral Treatment
7	N0397 Not Endorsed - Endorsement Removed	Hepatitis C: Prescribed Antiviral Therapy
8	N0400 Not Endorsed - Endorsement Removed	Paired Measure: Hepatitis C: Hepatitis B Vaccination (paired with 0399)
9	N0401 Not Endorsed - Endorsement Removed	Hepatitis C: Counseling Regarding Risk of Alcohol Consumption
17	N0403 Not Endorsed – Endorsement Removed	HIV/AIDS: Medical Visit

18	N0406 Not Endorsed – Endorsement Removed	HIV/AIDS: Adolescent and adult patients with HIV/AIDS who are prescribed potent Antiretroviral Therapy
19	N0407 Not Endorsed – Endorsement Removed	HIV/AIDS: HIV RNA control after six months of potent antiretroviral therapy
20	N0410 Not Endorsed – Endorsement Removed	HIV/AIDS: Sexually Transmitted Diseases - Syphilis Screening

Imaging

PQRS Measures to Include in Physician Compare and Value-Based Payment Modifier

Table Row #	Measure # and NQF Endorsement Status	Measure Title (Abbreviated)
5	0670 Endorsed	Cardiac stress imaging not meeting appropriate use criteria: Preoperative evaluation in low risk surgery patients
6	0562 Endorsed	Overutilization of Imaging Studies in Melanoma
8	0382 Endorsed	Oncology: Radiation Dose Limits to Normal Tissues

Measures to Retain or Include in Physician Quality Reporting System

Table Row #	Measure # and NQF Endorsement Status	Measure Title (Abbreviated)
1	M2444 Not Endorsed	American Board of Radiology/American Board of Medical Specialties/American College of Radiology/Physician Consortium for Performance Improvement: [DRAFT] Radiation Dose Optimization: Appropriateness: Follow-up CT Imaging for Incidental Pulmonary Nodules A
3	0509 Endorsed	Reminder system for mammograms
4	0510 Endorsed	Exposure time reported for procedures using fluoroscopy
7	M1099 Not Endorsed	262 Image Confirmation of Successful Excision of Image-Localized Breast Lesion

Table Row #	Measure # and NQF Endorsement Status	Measure Title (Abbreviated)
2	N0511 Not Endorsed - Endorsement Removed	Correlation With Existing Imaging Studies for All Patients Undergoing Bone Scintigraphy legitimately

Musculoskeletal

PQRS Measures to Include in Physician Compare and Value-Based Payment Modifier

Table Row #	Measure # and NQF Endorsement Status	Measure Title (Abbreviated)
1	0422 Endorsed	Functional status change for patients with knee impairments
2	0423 Endorsed	Functional status change for patients with hip impairments
3	0424 Endorsed	Functional status change for patients with foot/ankle impairments
4	0425 Endorsed	Functional status change for patients with lumbar spine impairments
5	0426 Endorsed	Functional status change for patients with shoulder impairments
6	0427 Endorsed	Functional status change for patients with elbow, wrist or hand impairments
7	0428 Endorsed	Functional status change for patients with general orthopedic impairments
24	0054 Endorsed	Arthritis: disease modifying antirheumatic drug (DMARD) therapy in rheumatoid arthritis

Measures to Retain or Include in Physician Quality Reporting System

Table Row #	Measure # and NQF Endorsement Status	Measure Title (Abbreviated)
10	M281 Not Endorsed	182 Functional Outcome Assessment in Chiropractic Care
11	0050 Endorsed	Osteoarthritis: Function and Pain Assessment
12	0051 Endorsed	Osteoarthritis: assessment for use of anti-inflammatory or analgesic over-the- counter (OTC) medications
13	0045 Endorsed	Osteoporosis:Communication with the Physician Managing On-going Care Post Fracture of Hip, Spine or Distal Radius for Men and Women Aged 50 Years and Older
14	0046 Endorsed	Osteoporosis: Screening or Therapy for Women Aged 65 Years and Older
15	0048 Endorsed	Osteoporosis: Management Following Fracture of Hip, Spine or Distal Radius for Men and Women Aged 50 Years and Older
16	0049 Endorsed	Osteoporosis: Pharmacologic Therapy for Men and Women Aged 50 Years and Older
25	M275 Not Endorsed	176 Rheumatoid Arthritis (RA): Tuberculosis Screening
26	M276 Not Endorsed	177 Rheumatoid Arthritis (RA): Periodic Assessment of Disease Activity
27	M277 Not Endorsed	178 Rheumatoid Arthritis (RA): Functional Status Assessment
28	M278 Not Endorsed	179 Rheumatoid Arthritis (RA): Assessment and Classification of Disease Prognosis
29	M279 Not Endorsed	180 Rheumatoid Arthritis (RA): Glucocorticoid Management

Table Row #	Measure # and NQF Endorsement Status	Measure Title (Abbreviated)
8	M2271 Not Endorsed	Functional Status assessment for knee replacement

9	M2272 Not Endorsed	Functional Status assessment for hip replacement
18	M2154 Not Endorsed	Osteoporosis: Current Level of Alcohol Use and Advice on Potentially Hazardous Drinking Prevention
19	M2155 Not Endorsed	Osteoporosis: Screen for Falls Risk Evaluation and Complete Falls Risk Assessment and Plan of Care
20	M2493 Not Endorsed	Osteoporosis: Calcium Intake Assessment and Counseling
21	M2494 Not Endorsed	Osteoporosis: DXA Scan
22	M2495 Not Endorsed	Osteoporosis: Pharmacologic Therapy
23	M2496 Not Endorsed	Osteoporosis: Vitamin D Intake Assessment and Counseling

Status to Be Determined for Retention in Physician Quality Reporting System

Table Row #	Measure # and NQF Endorsement Status	Measure Title (Abbreviated)
17	M2153 Not Endorsed	Osteoporosis: Status of Participation in Weight-bearing Exercise and Weight- bearing Exercise Advice

Discussion/Notes

 Workgroup members were split on retaining M2153 (Row #17) in the Physician Quality Reporting Program. Workgroup comments noted that private sector alignment (i.e., used in ABIM MOC programs) should not outweigh parsimony. MAP has previously recommended leveraging measurement data from MOC programs for multiple purposes to decrease reporting burden.

Neurological

Measures to Retain or Include in Physician Quality Reporting System

Table Row #	Measure # and NQF Endorsement Status	Measure Title (Abbreviated)
1	M1380 Not Endorsed	266 Epilepsy: Seizure Type(s) and Current Seizure Frequency(ies)
3	M1387 Not Endorsed	268: Epilepsy: Counseling for Women of Childbearing Potential with Epilepsy
4	M1807 Not Endorsed	289 Parkinson's Disease: Annual Parkinson's Disease Diagnosis Review
5	M1808 Not Endorsed	290 Parkinson's Disease: Psychiatric Disorders or Disturbances Assessment
6	M1809 Not Endorsed	291 Parkinson's Disease: Cognitive Impairment or Dysfunction Assessment
7	M1810 Not Endorsed	292 Parkinson's Disease: Querying about Sleep Disturbances
9	M1813 Not Endorsed	294 Parkinson's Disease: Medical and Surgical Treatment Options Reviewed

Table Row #	Measure # and NQF Endorsement Status	Measure Title (Abbreviated)
2	M1381 Not Endorsed	267 Epilepsy: Documentation of Etiology of Epilepsy or Epilepsy Syndrome
8	M1811 Not Endorsed	293 Parkinson's Disease: Rehabilitative Therapy Options

Obesity

PQRS Measures to Include in Physician Compare and Value-Based Payment Modifier

Table Row #	Measure # and NQF Endorsement Status	Measure Title (Abbreviated)
9	0024 Endorsed	Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents
10	0421 Endorsed	Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow- Up

Table Row #	Measure # and NQF Endorsement Status	Measure Title (Abbreviated)
1	M2826 Not Endorsed	Bariatric Lap Band Procedure 2: Unplanned reoperation within the 30 day postoperative period (2 of 3 Measures Group: Bariatric lap Band Procedure)
2	M2828 Not Endorsed	Bariatric Lap Band Procedure 1: latrogenic injury to adjacent organ/structure (1 of 3 Measures Group: Bariatric lap Band Procedure)
3	M2829 Not Endorsed	Bariatric Laparoscopic or Open Roux-en Y Gastric Bypass 1: Anastomotic Leak Intervention (1 of 6 Measures Group: Bariatric Laparoscopic or Open Roux-en Y Gastric Bypass)
4	M2830 Not Endorsed	Bariatric Laparoscopic or Open Roux-en Y Gastric Bypass 2: latrogenic injury to adjacent organ/structure (2 of 6 Measures Group: Bariatric Laparoscopic or Open Roux-en Y Gastric Bypass)
5	M2831 Not Endorsed	Bariatric Laparoscopic or Open Roux-en Y Gastric Bypass 3: Unplanned reoperation within the 30 day postoperative period (3 of 6 Measures Group: Bariatric Laparoscopic or Open Roux-en Y Gastric Bypass
6	M2832 Not Endorsed	Bariatric Laparoscopic or Open Roux-en Y Gastric Bypass 4: Unplanned hospital readmission within 30 days of principal procedure (4 of 6 Measures Group: Bariatric Laparoscopic or Open Roux-en Y Gastric Bypass)
7	M2833 Not Endorsed	Bariatric Laparoscopic or Open Roux-en Y Gastric Bypass 5: Surgical site infection (SSI) (5 of 6 Measures Group:Bariatric Laparoscopic or Open Roux-en Y Gastric Bypass)
8	M2835 Not Endorsed	Bariatric Sleeve Gastrectomy 1: Leak Intervention (1 of 6 Measures Group: Bariatric Sleeve Gastrectomy)

Perinatal and Reproduction

Table Row #	Measure # and NQF Endorsement Status	Measure Title (Abbreviated)
1	0651 Endorsed	Ultrasound determination of pregnancy location for pregnant patients with abdominal pain
2	0652 Endorsed	Rh immunoglobulin (Rhogam) for Rh negative pregnant women at risk of fetal blood exposure.
3	M2798 Not Endorsed	ACOG/NCQA/ AMA-PCPI: Maternity Care: Elective Delivery or Early Induction Without Medical Indication at >=37 and < 39 weeks (overuse)
4	M2801 Not Endorsed	ACOG/NCQA/ AMA-PCPI: Maternity Care: Post-Partum Follow-Up and Care Coordination

Measures to Retain or Include in Physician Quality Reporting System

Measures to Remove or Exclude from Physician Quality Reporting System

Table Row #	Measure # and NQF Endorsement Status	Measure Title (Abbreviated)
5	N0012 Not Endorsed	Prenatal Screening for Human Immunodeficiency Virus (HIV)
6	N0014 Not Endorsed	Prenatal Anti-D Immune Globulin

Status to Be Determined for inclusion in Physician Quality Reporting System

Table Row #	Measure # and NQF Endorsement Status	Measure Title (Abbreviated)
7	N0608 Not Endorsed – Endorsement Removed	Pregnant women that had HBsAg testing

Discussion/Notes

• Workgroup members were split on retaining N0608 (Row #7) in the Physician Quality Reporting System. Members sought clarification on why the measure should be retained despite losing NQF endorsement.

Respiratory

Measures to Retain or Include in Physician Quality Reporting System

Table Row #	Measure # and NQF Endorsement Status	Measure Title (Abbreviated)
1	0036 Endorsed	Use of appropriate medications for people with asthma
2	0047 Endorsed	Asthma: Pharmacologic Therapy for Persistent Asthma
3	M1249 Not Endorsed	231 Asthma: Tobacco Use Screening - Ambulatory Care Setting
4	M1250 Not Endorsed	232 Asthma: Tobacco Use Intervention - Ambulatory Care Setting
6	0091 Endorsed	COPD: spirometry evaluation
7	0102 Endorsed	COPD: inhaled bronchodilator therapy
8	0577 Endorsed	Use of Spirometry Testing in the Assessment and Diagnosis of COPD
9	0096 Endorsed	Empiric Antibiotic for Community-Acquired Bacterial Pneumonia
10	0147 Endorsed	Initial antibiotic selection for community-acquired pneumonia (CAP) in immunocompetent patients
12	0058 Endorsed	Avoidance of Antibiotic Treatment in Adults with Acute Bronchitis
13	0069 Endorsed	Appropriate treatment for children with upper respiratory infection (URI)
14	M2415 Not Endorsed	AAO- HNS/AMA- PCPI:Adult Sinusitis: Antibiotic Prescribed for Acute Sinusitis (Appropriate Use)
15	M2416 Not Endorsed	AAO- HNS/AMA- PCPI:Adult Sinusitis: Appropriate Choice of Antibiotic: Amoxicillin Prescribed for Acute Bacterial Sinusitis (Appropriate Use)
16	M1076 Not Endorsed	276 Sleep Apnea: Assessment of Sleep Symptoms
17	M1077 Not Endorsed	277 Sleep Apnea: Severity Assessment at Initial Diagnosis
18	M1078 Not Endorsed	278 Sleep Apnea: Positive Airway Pressure Therapy Prescribed
19	M1079 Not Endorsed	279 Sleep Apnea: Assessment of Adherence to Positive Airway Pressure Therapy

Table Row #	Measure # and NQF Endorsement Status	Measure Title (Abbreviated)
5	N0001 Not Endorsed - Endorsement Removed	Asthma: Assessment of Asthma Control
11	N0232 Not Endorsed - Endorsement Removed	Vital Signs for Community-Acquired Bacterial Pneumonia

Safety

PQRS Measures to Include in Physician Compare and Value-Based Payment Modifier

Table Row #	Measure # and NQF Endorsement Status	Measure Title (Abbreviated)
1	0101 Endorsed	Falls: Screening, Risk-Assessment, and Plan of Care to Prevent Future Falls
2	0326 Endorsed	Advance Care Plan
4	0486 Endorsed	Adoption of Medication e-Prescribing
8	0052 Endorsed	Use of Imaging Studies for Low Back Pain
13	0022 Endorsed	Use of High Risk Medications in the Elderly
14	0097 Endorsed	Medication Reconciliation
15	0419 Endorsed	Documentation of Current Medications in the Medical Record
19	0671 Endorsed	Cardiac stress imaging not meeting appropriate use criteria: Routine testing after percutaneous coronary intervention (PCI)
20	0672 Endorsed	Cardiac stress imaging not meeting appropriate use criteria: Testing in asymptomatic, low risk patients
27	0209 Endorsed	Comfortable Dying: Pain Brought to a Comfortable Level Within 48 Hours of Initial Assessment

Table Row #	Measure # and NQF Endorsement Status	Measure Title (Abbreviated)
3	M280 Not Endorsed	181 Elder Maltreatment Screen and Follow-Up Plan
5	0098 Endorsed	Urinary Incontinence: Assessment of Presence or Absence of Urinary Incontinence in Women Aged 65 Years and Older
6	0099 Endorsed	Urinary Incontinence: Characterization of Urinary Incontinence in Women Aged 65 Years and Older
7	0100 Endorsed	Urinary Incontinence: Plan of Care for Urinary Incontinence in Women Aged 65 Years and Older
9	0313 Endorsed	Back Pain: Advice Against Bed Rest
10	0314 Endorsed	Back Pain: Advice for Normal Activities
12	0322 Endorsed	Back Pain: Initial Visit
16	0555 Endorsed	Monthly INR Monitoring for Individuals on Warfarin

Measures to Retain or Include in Physician Quality Reporting System			
17	M2951 Not Endorsed	Tuberculosis Prevention for Psoriasis and Psoriatic Arthritis Patients on a Biological Immune Response Modifier	
21	M1020 Not Endorsed	245 Chronic Wound Care: Use of Wound Surface Culture Technique in Patients with Chronic Skin Ulcers (overuse measure)	
22	M1021 Not Endorsed	246 Chronic Wound Care: Use of Wet to Dry Dressings in Patients with Chronic Skin Ulcers (overuse measure)	
23	M2418 Not Endorsed	AAO- HNS/AMA- PCPI:Adult Sinusitis: Computerized Tomography for Acute Sinusitis (overuse)	
24	M2419 Not Endorsed	AAO- HNS/AMA- PCPI:Adult Sinusitis: More than 1 Computerized Tomography (CT) Scan Within 90 Days for Chronic Sinusitis (Overuse)	
25	M2441 Not Endorsed	American Board of Medical Specialties/American Board of Allergy and Immunology/American Academy of Dermatology/American Association of Immunologists/Physician Consortium for Performance Improvement: [DRAFT]: Atopic Dermatitis: Overuse: Role of Antihistami	
28	0420 Endorsed	Pain Assessment and Follow-Up	
29	0464 Endorsed	Anesthesiology and Critical Care: Prevention of Catheter-Related Bloodstream Infections (CRBSI) – Central Venous Catheter (CVC) Insertion Protocol	
31	0372 Endorsed	Intensive Care Unit Venous Thromboembolism Prophylaxis	

Table Row #	Measure # and NQF Endorsement Status	Measure Title (Abbreviated)
26	M2449 Not Endorsed	Preventive Cardiology Composite: Appropriate use of aspirin or other antiplatelet anticoagulant therapy
32	N0503 Not Endorsed - Endorsement Removed	Anticoagulation for acute pulmonary embolus patients
33	M2283 Not Endorsed	ASPS/AMA- PCPI/NCQA: Chronic Wound Care: Patient education regarding long term compression therapy

Status to Be Determined for Retention in Physician Quality Reporting System

Table Row #	Measure # and NQF Endorsement Status	Measure Title (Abbreviated)
11	0319 Endorsed	Back Pain: Physical Exam
30	0493 Endorsed	Participation by a physician or other clinician in systematic clinical database registry that includes consensus endorsed quality measures

Discussion/Notes

- Workgroup members were split on retaining NQF #0319 (Row #11) in the Physician Quality Reporting System. Comments indicated this is a low-bar process measure as it assesses if a physical exam is conducted for patients experiencing back pain. MAP has previously suggested that all NQF-endorsed measures be included in PQRS.
- Workgroup members were split on retaining NQF #0493 (Row #30) in the Physician Quality Reporting System. Comments noted that the proposed rule indicates that the measure may be redundant given the inclusion of Qualified Clinical Data Registries and therefore should be removed.

Surgery

Table Row #	Measure # and NQF Endorsement Status	Measure Title (Abbreviated)
1	0114 Endorsed	Risk-Adjusted Post-operative Renal Failure
2	0115 Endorsed	Risk-Adjusted Surgical Re-exploration
3	0116 Endorsed	Anti-Platelet Medication at Discharge
4	0117 Endorsed	Beta Blockade at Discharge
5	0118 Endorsed	Anti-Lipid Treatment Discharge
6	0129 Endorsed	Risk-Adjusted Prolonged Intubation (Ventilation)
7	0130 Endorsed	Risk-Adjusted Deep Sternal Wound Infection Rate
8	0131 Endorsed	Risk-Adjusted Stroke/Cerebrovascular Accident
9	0134 Endorsed	Use of Internal Mammary Artery (IMA) in Coronary Artery Bypass Graft (CABG)
10	0236 Endorsed	Pre-op beta blocker in patient with isolated CABG (2)
11	0637 Endorsed	Discontinuation of Prophylactic Antibiotics (Cardiac Procedures)
12	M2890 Not Endorsed	HRS-3 Implantable Cardioverter-Defibrillator (ICD) Complications Rate.
13	0239 Endorsed	Venous Thromboembolism (VTE) Prophylaxis
14	0268 Endorsed	Selection of Prophylactic Antibiotic: First OR Second Generation Cephalosporin
15	0269 Endorsed	Timing of Prophylactic Antibiotics - Administering Physician
16	0270 Endorsed	Timing of Antibiotic Prophylaxis: Ordering Physician
17	0271 Endorsed	Discontinuation of Prophylactic Antibiotics (Non-Cardiac Procedures)
18	0454 Endorsed	Anesthesiology and Critical Care: Perioperative Temperature Management
19	M2789 Not Endorsed	Ventral Hernia 5: Surgical site infection (SSI) (1 of 5 : Measures Group Ventral Hernia)
20	M2790 Not Endorsed	Ventral Hernia 4: Unplanned hospital readmission within 30 days of principal procedure (4 of 5 : Measures Group Ventral Hernia)
21	M2916 Not Endorsed	Patient-centered Surgical Risk Assessment and Communication: the percent of patients who underwent non-emergency major surgery who received preoperative risk assessment for procedure-specific postoperative

		complications using a data-based, patient- specific
22	M2957 Not Endorsed	Ventral Hernia 1: latrogenic injury to adjacent organ/structure (1 of 5 : Measures Group Ventral Hernia)
23	M2959 Not Endorsed	Ventral Hernia 3: Unplanned reoperation within the 30 day postoperative period (3 of 5 : Measures Group Ventral Hernia)
26	M2427 Not Endorsed	Total Knee Replacement: Preoperative Antibiotic Infusion with Proximal Tourniquet
27	M2429 Not Endorsed	Total Knee Replacement: Venous Thromboembolic and Cardiovascular Risk Evaluation
28	M2939 Not Endorsed	Shared Decision-Making: Trial of Conservative (Non-surgical) Therapy
29	M2907 Not Endorsed	Neurosurgery: Initial Visit (Similar to PQRS Measure 148)
30	0458 Endorsed	Pulmonary Function Tests before major anatomic lung resection (pneumonectomy, lobectomy)
35	M1072 Not Endorsed	257 Statin Therapy at Discharge after Lower Extremity Bypass (LEB)
36	M1073 Not Endorsed	258 Rate of Open Elective Repair of Small or Moderate Abdominal Aortic Aneurysms (AAA) without Major Complications (Discharged to Home by Post-Operative Day #7)
37	M1074 Not Endorsed	259 Rate of Elective Endovascular Aortic Repair (EVAR) of Small or Moderate Abdominal Aortic Aneurysms (AAA) without Major Complications (Discharged to Home by Post-Operative Day #2)
38	M1075 Not Endorsed	260 Rate of Carotid Endarterectomy for Asymptomatic Patients, without Major Complications (discharged to home no later than post-operative day #2)
39	M2930 Not Endorsed	Rate of Major Complications (Discharged to Home by Post- Operative Day #2) Carotid Artery Stenting (CAS) for Asymptomatic Patients, without Major Complications (Discharged to Home by Post-Operative Day #2

Table Row #	Measure # and NQF Endorsement Status	Measure Title (Abbreviated)
24	M2424 Not Endorsed	Total Knee Replacement: Coordination of Post Discharge Care
34	M1071 Not Endorsed	256 Surveillance after Endovascular Abdominal Aortic Aneurysm Repair (EVAR)

Status to Be Determined for inclusion in Physician Quality Reporting System

Table Row #	Measure # and NQF Endorsement Status	Measure Title (Abbreviated)
25	M2425 Not Endorsed	Total Knee Replacement: Identification of Implanted Prosthesis in Operative Report

Status to Be Determined for inclusion in Physician Compare and Value-Based Payment Modifier			
31	1534 Endorsed	In-hospital mortality following elective EVAR of AAAs	
32	1540 Endorsed	Postoperative Stroke or Death in Asymptomatic Patients undergoing Carotid Endarterectomy	
33	1543 Endorsed	Postoperative Stroke or Death in Asymptomatic Patients undergoing Carotid Artery Stenting (CAS)	

Discussion/Notes

- Workgroup members were split on retaining M2425 (Row #25) in the Physician Quality Reporting System. Comments indicated that it is a low-bar process measure as it only assesses documentation of use of a device.
- Workgroup members were split on including NQF #1534 (Row #31), NQF #1540 (Row #32), and NQF #1543 (Row #33) in Physician Compare and Value-Based Payment Modifier program. Comments in support of including the measures indicate that they capture important information for patient decision-making.